Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Arcus Biosciences stock

Learn how to easily invest in Arcus Biosciences stock.

Arcus Biosciences Inc is a biotechnology business based in the US. Arcus Biosciences shares (RCUS) are listed on the NYSE and all prices are listed in US Dollars. Arcus Biosciences employs 366 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Arcus Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RCUS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Arcus Biosciences stock price (NYSE: RCUS)

Use our graph to track the performance of RCUS stocks over time.

Arcus Biosciences shares at a glance

Information last updated 2022-06-25.
Latest market close$24.42
52-week range$16.74 - $49.10
50-day moving average $22.99
200-day moving average $32.69
Wall St. target price$57.20
PE ratio 33.5302
Dividend yield $0 (0%)
Earnings per share (TTM) $0.76

Buy Arcus Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
$0
$0
N/A
Financial advice powered by relationships, not commissions.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arcus Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arcus Biosciences price performance over time

Historical closes compared with the close of $24.42 from 2022-06-28

1 week (2022-06-23) -2.24%
1 month (2022-05-26) 34.18%
3 months (2022-03-30) -26.89%
6 months (2021-12-29) -42.11%
1 year (2021-06-30) -11.07%
2 years (2020-06-30) -1.29%
3 years (2019-06-28) 207.17%
5 years (2017-06-26) N/A

Is Arcus Biosciences stock undervalued or overvalued?

Valuing Arcus Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arcus Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Arcus Biosciences's P/E ratio

Arcus Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Arcus Biosciences shares trade at around 34x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Arcus Biosciences's EBITDA

Arcus Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $64.3 million.

The EBITDA is a measure of a Arcus Biosciences's overall financial performance and is widely used to measure a its profitability.

Arcus Biosciences financials

Revenue TTM $391.4 million
Operating margin TTM 15.28%
Gross profit TTM $126.5 million
Return on assets TTM 3.02%
Return on equity TTM 7.86%
Profit margin 14.67%
Book value $11.12
Market capitalisation $1.8 billion

TTM: trailing 12 months

Arcus Biosciences share dividends

We're not expecting Arcus Biosciences to pay a dividend over the next 12 months.

Arcus Biosciences share price volatility

Over the last 12 months, Arcus Biosciences's shares have ranged in value from as little as $16.74 up to $49.1. A popular way to gauge a stock's volatility is its "beta".

RCUS.US volatility(beta: 1.01)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Arcus Biosciences's is 1.0115. This would suggest that Arcus Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Arcus Biosciences overview

Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L. P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co.

Frequently asked questions

What percentage of Arcus Biosciences is owned by insiders or institutions?
Currently 32.919% of Arcus Biosciences shares are held by insiders and 68.88% by institutions.
How many people work for Arcus Biosciences?
Latest data suggests 366 work at Arcus Biosciences.
When does the fiscal year end for Arcus Biosciences?
Arcus Biosciences's fiscal year ends in December.
Where is Arcus Biosciences based?
Arcus Biosciences's address is: 3928 Point Eden Way, Hayward, CA, United States, 94545
What is Arcus Biosciences's ISIN number?
Arcus Biosciences's international securities identification number is: US03969F1093
What is Arcus Biosciences's CUSIP number?
Arcus Biosciences's Committee on Uniform Securities Identification Procedures number is: 03969F109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site